These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12437503)

  • 21. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
    Mullershausen F; Russwurm M; Friebe A; Koesling D
    Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
    Conti CR; Pepine CJ; Sweeney M
    Am J Cardiol; 1999 Mar; 83(5A):29C-34C. PubMed ID: 10078540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats.
    Angulo J; Cuevas P; Gabancho S; Gonzalez-Corrochano R; Videla S; Saenz de Tejada I
    J Sex Med; 2005 May; 2(3):341-6. PubMed ID: 16422865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
    Hallén K; Wiklund NP; Gustafsson LE
    Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
    Lincoln TM
    Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
    [No Abstract]   [Full Text] [Related]  

  • 27. Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Sui Z; Guan J; Macielag MJ; Jiang W; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Clancy J
    J Med Chem; 2002 Sep; 45(19):4094-6. PubMed ID: 12213052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
    Hemnes AR; Champion HC
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):293-300. PubMed ID: 16716091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction.
    Fisher WA; Rosen RC; Eardley I; Niederberger C; Nadel A; Kaufman J; Sand M
    J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
    Pissarnitski D
    Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Yu G; Mason HJ; Wu X; Wang J; Chong S; Dorough G; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Adam L; Krupinski J; Macor JE
    J Med Chem; 2001 Mar; 44(7):1025-7. PubMed ID: 11297448
    [No Abstract]   [Full Text] [Related]  

  • 34. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise.
    Traverse JH; Chen YJ; Du R; Bache RJ
    Circulation; 2000 Dec; 102(24):2997-3002. PubMed ID: 11113052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of nitric oxide in erectile dysfunction: implications for medical therapy.
    Burnett AL
    J Clin Hypertens (Greenwich); 2006 Dec; 8(12 Suppl 4):53-62. PubMed ID: 17170606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphodiesterase inhibitors.
    Boswell-Smith V; Spina D; Page CP
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Is it safe for cardiological patients to take sildenafil (viagra) to correct erectile dysfunction? (lectures)].
    Metelitsa VI
    Ter Arkh; 2000; 72(6):67-9. PubMed ID: 10900657
    [No Abstract]   [Full Text] [Related]  

  • 38. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Curr Pharm Des; 2010 May; 16(14):1619-33. PubMed ID: 20201788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.